PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
60 hedge funds and large institutions have $84.3M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
13% more call options, than puts
Call options by funds: $89K | Put options by funds: $79K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
60
Holding in Top 10
1
Calls
$89K
Puts
$79K
Top Buyers
| 1 | +$425K | |
| 2 | +$406K | |
| 3 | +$350K | |
| 4 |
Millennium Management
New York
|
+$281K |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$200K |
Top Sellers
| 1 | -$1.65M | |
| 2 | -$280K | |
| 3 | -$256K | |
| 4 |
Renaissance Technologies
New York
|
-$146K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$142K |